CATT 2-year results add fuel to Avastin/Lucentis debate, with implications for Eylea
This article was originally published in Scrip
Executive Summary
Updated results from a US government-funded study showed that long-term treatment with either Genentech's Lucentis (ranibizumab) or the much cheaper Avastin (bevacizumab) resulted in similar levels of visual improvement in patients with advanced age-related macular degeneration (AMD) – with clarity of vision with monthly treatments only slightly better than the as-needed (PRN) treatment group.